Free tool
FAERS Monitor: Entyvio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761133 or its brand name (Entyvio, Vedolizumab). Reports on generic versions are filed under their own applications.
Reports
86,821
Serious
75,213
87% of reports
Hospitalization
25,407
Death reported
4,311
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use22,425
- colitis ulcerative15,710
- crohn^s disease11,435
- drug ineffective10,034
- diarrhoea8,782
- abdominal pain7,505
- fatigue6,395
- haematochezia6,172
- frequent bowel movements5,300
- arthralgia4,810
- malaise4,398
- nausea4,215
- headache4,163
- inappropriate schedule of product administration4,078
- product dose omission issue3,868
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 128 |
| 2015 | 1,680 |
| 2016 | 2,930 |
| 2017 | 3,562 |
| 2018 | 4,739 |
| 2019 | 5,511 |
| 2020 | 7,459 |
| 2021 | 10,537 |
| 2022 | 9,447 |
| 2023 | 11,051 |
| 2024 | 12,190 |
| 2025 | 11,229 |
| 2026 | 6,355 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,967,338 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colitis ulcerativeSignal | 15,710 | 130.7 | 128.3 | 1,314,527 |
| frequent bowel movementsSignal | 5,300 | 58.9 | 57.2 | 242,684 |
| haematocheziaSignal | 6,172 | 30.4 | 29.6 | 156,093 |
| abdominal painSignal | 7,505 | 8.0 | 7.9 | 45,284 |
| off label useSignal | 22,425 | 6.3 | 6.3 | 102,563 |
| inappropriate schedule of product administrationSignal | 4,078 | 5.6 | 5.4 | 15,129 |
| diarrhoeaSignal | 8,782 | 3.3 | 3.3 | 14,547 |
| product dose omission issueSignal | 3,868 | 3.2 | 3.1 | 5,908 |
| arthralgiaSignal | 4,810 | 2.8 | 2.7 | 5,711 |
| malaiseSignal | 4,398 | 2.4 | 2.4 | 3,791 |
| fatigue | 6,395 | 2.0 | 2.0 | 3,283 |
| drug ineffective | 10,034 | 1.9 | 1.8 | 4,155 |
| headache | 4,163 | 1.6 | 1.6 | 991 |
| nausea | 4,215 | 1.3 | 1.3 | 287 |
| crohn^s disease | 11,435 | 0.0 | 0.0 | 2,762,819 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.